Montag, 29. April 2024
Navigation öffnen
Anzeige:
Wefra Programatic
 
JOURNAL ONKOLOGIE – STUDIE
ARTEMIDE-Bil01

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

Rekrutierend

NCT-Nummer:
NCT06109779

Studienbeginn:
Dezember 2023

Letztes Update:
03.04.2024

Wirkstoff:
Rilvegostomig, Placebo, Capecitabine, Gemcitabine/Cisplatin, S-1 [Tegafur/Oteracil/gimeracil]

Indikation (Clinical Trials):
Biliary Tract Neoplasms

Geschlecht:
Alle

Altersgruppe:
Erwachsene (18+)

Phase:
Phase 3

Sponsor:
AstraZeneca

Collaborator:
-

Kontakt

AstraZeneca Clinical Study Information Center
Kontakt:
Phone: 1-877-240-9479
E-Mail: information.center@astrazeneca.com
» Kontaktdaten anzeigen

Studienlocations
(3 von 158)

Research Site
13353 Berlin
(Berlin)
GermanyNoch nicht rekrutierend» Google-Maps
Research Site
53127 Bonn
(Nordrhein-Westfalen)
GermanyNoch nicht rekrutierend» Google-Maps
Research Site
44137 Dortmund
(Nordrhein-Westfalen)
GermanyNoch nicht rekrutierend» Google-Maps
Research Site
01307 Dresden
(Sachsen)
GermanyNoch nicht rekrutierend» Google-Maps
Research Site
91054 Erlangen
(Bayern)
GermanyNoch nicht rekrutierend» Google-Maps
Research Site
45122 Essen
(Nordrhein-Westfalen)
GermanyNoch nicht rekrutierend» Google-Maps
Research Site
73730 Esslingen
(Baden-Württemberg)
GermanyNoch nicht rekrutierend» Google-Maps
Research Site
60488 Frankfurt
(Hessen)
GermanyNoch nicht rekrutierend» Google-Maps
Research Site
22763 Hamburg
(Hamburg)
GermanyNoch nicht rekrutierend» Google-Maps
Research Site
69120 Heidelberg
(Baden-Württemberg)
GermanyNoch nicht rekrutierend» Google-Maps
Research Site
50937 Köln
(Nordrhein-Westfalen)
GermanyNoch nicht rekrutierend» Google-Maps
Research Site
4103 Leipzig
(Sachsen)
GermanyNoch nicht rekrutierend» Google-Maps
Research Site
23538 Luebeck
(Schleswig-Holstein)
GermanyNoch nicht rekrutierend» Google-Maps
Research Site
81377 München
(Bayern)
GermanyNoch nicht rekrutierend» Google-Maps
Research Site
81737 München
(Bayern)
GermanyNoch nicht rekrutierend» Google-Maps
Research Site
48149 Münster
(Nordrhein-Westfalen)
GermanyNoch nicht rekrutierend» Google-Maps
Research Site
70174 Stuttgart
(Baden-Württemberg)
GermanyNoch nicht rekrutierend» Google-Maps
Research Site
89081 Ulm
(Baden-Württemberg)
GermanyNoch nicht rekrutierend» Google-Maps
Research Site
35233 Birmingham
United StatesNoch nicht rekrutierend» Google-Maps
Research Site
85054 Phoenix
United StatesNoch nicht rekrutierend» Google-Maps
Research Site
90089 Los Angeles
United StatesNoch nicht rekrutierend» Google-Maps
Research Site
92868 Orange
United StatesNoch nicht rekrutierend» Google-Maps
Research Site
94305 Stanford
United StatesNoch nicht rekrutierend» Google-Maps
Research Site
90048 West Hollywood
United StatesNoch nicht rekrutierend» Google-Maps
Research Site
80045 Aurora
United StatesNoch nicht rekrutierend» Google-Maps
Research Site
20007 Washington
United StatesNoch nicht rekrutierend» Google-Maps
Research Site
32224 Jacksonville
United StatesNoch nicht rekrutierend» Google-Maps
Research Site
60637 Chicago
United StatesNoch nicht rekrutierend» Google-Maps
Research Site
52242 Iowa City
United StatesNoch nicht rekrutierend» Google-Maps
Research Site
66160 Kansas City
United StatesNoch nicht rekrutierend» Google-Maps
Research Site
40506 Lexington
United StatesNoch nicht rekrutierend» Google-Maps
Research Site
70121 New Orleans
United StatesNoch nicht rekrutierend» Google-Maps
Research Site
21201 Baltimore
United StatesNoch nicht rekrutierend» Google-Maps
Research Site
55905 Rochester
United StatesNoch nicht rekrutierend» Google-Maps
Research Site
63110 Saint Louis
United StatesNoch nicht rekrutierend» Google-Maps
Research Site
11725 Commack
United StatesNoch nicht rekrutierend» Google-Maps
Research Site
11501 Mineola
United StatesNoch nicht rekrutierend» Google-Maps
Research Site
19111 Philadelphia
United StatesNoch nicht rekrutierend» Google-Maps
Research Site
19144 Philadelphia
United StatesNoch nicht rekrutierend» Google-Maps
Research Site
75246 Dallas
United StatesNoch nicht rekrutierend» Google-Maps
Research Site
75702 Tyler
United StatesNoch nicht rekrutierend» Google-Maps
Research Site
98684 Vancouver
United StatesNoch nicht rekrutierend» Google-Maps
Research Site
91350-200 Porto Alegre
BrazilNoch nicht rekrutierend» Google-Maps
Research Site
01246-000 Sao Paulo
BrazilNoch nicht rekrutierend» Google-Maps
Research Site
01327-001 Sao Paulo
BrazilNoch nicht rekrutierend» Google-Maps
Research Site
L5M 2N1 Mississauga
CanadaNoch nicht rekrutierend» Google-Maps
Research Site
75248 Paris Cedex 5
FranceNoch nicht rekrutierend» Google-Maps
Research Site
31059 Toulouse Cedex 9
FranceNoch nicht rekrutierend» Google-Maps
Research Site
00000 Hong Kong
Hong KongNoch nicht rekrutierend» Google-Maps
Research Site
73039 Tricase, Lecce
ItalyNoch nicht rekrutierend» Google-Maps
Research Site
464-8681 Nagoya-shi
JapanNoch nicht rekrutierend» Google-Maps
Research Site
13620 Seongnam-si
Korea, Republic ofRekrutierend» Google-Maps
Research Site
97-200 Tomaszów Mazowiecki
PolandNoch nicht rekrutierend» Google-Maps
Research Site
08908 L'Hospitalet de Llobregat
SpainNoch nicht rekrutierend» Google-Maps
Research Site
34098 Fatih-Istanbul
TurkeyNoch nicht rekrutierend» Google-Maps
Research Site
CB2 0QQ Cambridge
United KingdomNoch nicht rekrutierend» Google-Maps
Research Site
B15 2WB Edgbaston
United KingdomNoch nicht rekrutierend» Google-Maps
Research Site
G12 0YN Glasgow, Scotland
United KingdomNoch nicht rekrutierend» Google-Maps
Research Site
NW3 2QG London
United KingdomNoch nicht rekrutierend» Google-Maps
Research Site
WC1E 6BT London
United KingdomNoch nicht rekrutierend» Google-Maps
Research Site
M20 4BX Manchester
United KingdomNoch nicht rekrutierend» Google-Maps
Research Site
SM2 5PT Sutton
United KingdomNoch nicht rekrutierend» Google-Maps
Alle anzeigen

Studien-Informationen

Detailed Description:

This is a Phase III, randomized, double-blind, placebo-controlled, multicenter, global study

to assess the efficacy and tolerability of rilvegostomig compared to placebo in combination

with investigator's choice of chemotherapy (capecitabine, S-1(tegafur/ gimeracil/ oteracil)

or gemcitabine/cisplatin) as adjuvant treatment in participants with BTC after resection with

curative intent. This study will be conducted in patients with BTC who are at risk of

recurrence after resection with curative intent.

Ein-/Ausschlusskriterien

Inclusion Criteria:

- Histologically confirmed adenocarcinoma of the biliary tract (intrahepatic or

extrahepatic) after macroscopically complete resection (R0 or R1)

- Provision of a tumor sample collected at surgical resection.

- Randomization within 12 weeks after resection with adequate healing and removal of

drains.

- Confirmed to be disease-free by imaging within 28 days prior to randomization.

- Eastern Cooperative Oncology Group performance status of 0 or 1

Exclusion Criteria:

- Participants with locally-advanced, unresectable, or metastatic disease at initial

diagnosis.

- Ampullary cancer, neuroendocrine, mixed neuroendocrine and non-neuroendocrine

neoplasms and nonepithelial tumors.

- Any anti-cancer therapy for BTC prior to surgery

- Active or prior documented autoimmune or inflammatory disorders or any severe or

uncontrolled systemic disease

- Current or prior use of immunosuppressive medication within 14 days before the first

dose

- Thromboembolic event within 3 months

- Active HBV or HCV infection unless treated.

Studien-Rationale

Primary outcome:

1. Recurrence free survival (RFS) for Arm A vs. Arm B (Time Frame - Approximately 5 years):
Recurrence-free survival (RFS) is defined as the time from randomization until the date of radiological recurrence guided by RECIST 1.1 or death due to any cause, whichever occurs first.



Secondary outcome:

1. Overall Survival (OS) for Arm A vs. Arm B (Time Frame - up to 7 years):
Overall survival is defined as the time from randomization until the date of death due to any cause.

Studien-Arme

  • Experimental: Arm A
    Rilvegostomig IV infusion + Investigator choice of chemotherapy (Capecitabine or Gemcitabine/Cisplatin or S-1)
  • Placebo Comparator: Arm B
    Placebo IV infusion + Investigator choice of chemotherapy (Capecitabine or Gemcitabine/Cisplatin or S-1)

Geprüfte Regime

  • Rilvegostomig:
    Rilvegostomig IV (intravenous) Q3W
  • Placebo:
    Placebo IV (intravenous) Q3W
  • Capecitabine:
    Capecitabine (Oral) 1250 mg/m2 BID (twice daily) for 2 weeks on/1 week off in 21-day cycles or per local practice
  • Gemcitabine/Cisplatin:
    Gemcitabine/Cisplatin IV (Intravenous) 1000 mg/m2 plus cisplatin 25 mg/m2 on Day 1 and Day 8 of each 21-day cycle
  • S-1 [Tegafur/Oteracil/gimeracil]:
    S-1 [Tegafur/Oteracil/gimeracil] (Oral) BSA (body surface area)-based (40, 50, or 60 mg) BID for 4 weeks on 2 weeks off in 42-day cycles

Quelle: ClinicalTrials.gov


Sie können folgenden Inhalt einem Kollegen empfehlen:

"Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)"

Bitte tragen Sie auch die Absenderdaten vollständig ein, damit Sie der Empfänger erkennen kann.

Die mit (*) gekennzeichneten Angaben müssen eingetragen werden!

Die Verwendung Ihrer Daten für den Newsletter können Sie jederzeit mit Wirkung für die Zukunft gegenüber der MedtriX GmbH - Geschäftsbereich rs media widersprechen ohne dass Kosten entstehen. Nutzen Sie hierfür etwaige Abmeldelinks im Newsletter oder schreiben Sie eine E-Mail an: rgb-info[at]medtrix.group.